Could BRAF inhibition be a viable neoadjuvant strategy?
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Analysis of outcomes in patients with locoregional BRAF V600E-mutant melanoma who received BRAF inhibitor (BRAFi) therapy at Moffitt Cancer Center.
15 patients: 11 received vemurafenib alone; 4 who received combination dabrafenib + trametinib.
25.4 months median follow-up.
73.3% objective response (RECIST).
Pathologic responses: complete: 2 patients; partial: 2 patients; none: 2 patients.
6 patients underwent resection f...